Nektar Therapeutics 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Nektar Therapeutics details its 2024 financial performance and provides updates on its key drug development programs, including rezpegaldesleukin and NKTR-255.
NASDAQ
Nektar Therapeutics' 2023 annual report highlights a strategic shift towards immunotherapy, focusing on key drug candidates and cost restructuring efforts.